Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis (EVIDENCES VI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03863574
Recruitment Status : Not yet recruiting
First Posted : March 5, 2019
Last Update Posted : April 9, 2019
Sponsor:
Information provided by (Responsible Party):
Zydus Discovery DMCC

Brief Summary:
This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.

Condition or disease Intervention/treatment Phase
Non Alcoholic Steatohepatitis Drug: Saroglitazar Magnesium 2mg Drug: Saroglitazar Magnesium 4mg Drug: Placebos Phase 2

Detailed Description:

Patients clinically suspected of NASH will be invited for a screening programme for inclusion in the study. Patients will be screened according to the inclusion and exclusion criteria. Clinical evaluation will be conducted for baseline characteristics and anthropometry measurements such as body weight and height.

After clinical evaluations, all baseline safety and efficacy parameters will be recorded as per Visit Schedule. All laboratory collections will be performed following overnight fasting (at least 8 hrs).

Following confirmation of all clinical and laboratory inclusion and exclusion criteria, patients will continue into the screening period. During the screening period liver biopsy will be performed. However, if a biopsy was performed within 6 months the slides and biopsy material, or block, must be made available for baseline documentation. Such Patients, whose historical biopsy report is available, should not use medication suspected of having an effect on NASH from the 3 months prior to the screening.

Liver biopsy will be performed to confirm the diagnosis of NASH and record a baseline NAFLD Activity Score. The histological evidence of NASH is defined as NAS ≥ 4 with a minimum score of 1 for all of its three components [steatosis, hepatocyte ballooning and lobular inflammation].

Following confirmation of inclusion/exclusion criteria and upon histological confirmation of NASH by liver biopsy, patients will be enrolled into the study.

Eligible patients will be randomly assigned to receive Saroglitazar Magnesium 2 mg or 4 mg or placebo in a 2:2:1 ratio for 24 weeks.

Upon completion of 24 weeks of treatment, liver biopsy will be performed and the NAFLD Activity Score recorded.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 2 mg and 4 mg in Patients With Non-alcoholic Steatohepatitis
Estimated Study Start Date : April 15, 2019
Estimated Primary Completion Date : September 2, 2020
Estimated Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Magnesium

Arm Intervention/treatment
Experimental: Saroglitazar Magnesium 2 mg
Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Saroglitazar Magnesium 2mg
Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.

Experimental: Saroglitazar Magnesium 4 mg
Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Saroglitazar Magnesium 4mg
Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.

Placebo Comparator: Placebo
Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
Drug: Placebos
Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.




Primary Outcome Measures :
  1. NAS Score (NAFLD Activity Score) [ Time Frame: Baseline to Week 24 ]
    The primary endpoint is to assess the changes in NAFLD Activity Score (NAS) at week 24 from baseline and with no worsening of fibrosis in NASH patients.


Secondary Outcome Measures :
  1. To evaluate the percentage of responders in the treatment groups. [ Time Frame: Baseline to Week 24 ]
    Responder is defined as a decrease from baseline of at least 2 points spread across at least 2 of the NAS components [steatosis, hepatocyte ballooning, and lobular inflammation] with no worsening of fibrosis.

  2. Percentage of responders defined by the disappearance of steatohepatitis. [ Time Frame: Baseline to Week 24 ]
    Percentage of responders defined by the disappearance of steatohepatitis.

  3. Changes in the stage of steatosis, lobular inflammation and ballooning. [ Time Frame: Baseline to Week 24 ]
    Changes in the stage of steatosis, lobular inflammation and ballooning by evaluating the NAS Score (NAFLD Activity Score)

  4. Changes in the stage of fibrosis. [ Time Frame: Baseline to Week 24 ]
    Changes in the stage of fibrosis by evaluating the Fibrosis stages

  5. Changes in the liver function tests. [ Time Frame: Baseline to Week 24 ]
    Liver function tests include ALT, AST, ALP, direct bilirubin, GGT, total proteins and albumin.

  6. Changes in the lipid profile. [ Time Frame: Baseline to Week 24 ]
    Evaluation of Lipid profile parameters

  7. Changes in the glycemic control and insulin resistance. [ Time Frame: Baseline to Week 24 ]
    Evaluation of glycemic control and insulin resistance.

  8. To assess incidence of Adverse Events of Saroglitazar Magnesium 2 mg and 4 mg in patients with non-alcoholic steatohepatitis. [ Time Frame: Baseline to Week 24 ]
    Safety will be assessed during the study period through the reporting of AEs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients able to provide written informed consent for participation in this trial.
  2. Males or females, 18 to 75 years of age, both inclusive.
  3. Female must be either of non-child bearing potential (surgically sterilized at least 6 months prior to screening or postmenopausal) or using one or more methods of contraception.
  4. Histologic confirmation of NASH without cirrhosis (fibrosis stage 0, 1, 2, or 3) from liver biopsy performed either during the screening period or no more than 6 months prior to the first visit, with a NAS of ≥4 and a score of at least 1 in each (steatosis scored 0-3, ballooning scored 0-2, and lobular inflammation scored 0-3). If biopsy was performed within 6 months of screening, the slides, biopsy material or block should be available for baseline documentation. Such patients, whose historical biopsy report is available, should not use medications suspected of having an effect on NASH for at least 3 months prior to the screening.
  5. BMI ≥25 kg/m2.
  6. For hypertensive patients, blood pressure must be controlled by a stable dose of antihypertensive medications for at least 3 months prior to screening (and the stable dose can be maintained throughout the study)
  7. Patients with type 2 diabetes mellitus may be included if they fulfil the following criteria;

    1. Stable therapeutic regimen as defined by no changes in oral agents or dose for at least 3 months before screening and the stable dose can be maintained throughout the study.
    2. HbA1c ≤ 9.5%
  8. Patients agree to comply with the study procedure.

Exclusion Criteria:

  1. Pregnant and lactating female.
  2. Positive pregnancy test.
  3. Patients with history of myopathies or evidence of active muscle diseases.
  4. Patients with history of alcohol consumption of >30 gm/day for men, >20 gm/day for women for consecutive previous 2 years and/or drug abuse.
  5. Known allergy, sensitivity or intolerance to the study drug or formulation ingredients.
  6. Participation in an interventional clinical study and/or receipt of any investigational medication within 3 months prior to screening.
  7. History of malignancy in the past 5 years and/or active neoplasm with the exception of superficial, non-melanoma, skin cancer.
  8. Any of the following laboratory values at screening:

    1. Direct bilirubin >1.5 mg/dL,
    2. Serum albumin <2.5 g/dL.
    3. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2.
    4. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >200 IU/L.
    5. Patient with international normalized ratio (INR) >1.5.
    6. Creatinine kinase ≥ 1.5 ULN.
    7. Lipase ≥ULN.
    8. Amylase ≥ ULN.
  9. Unstable cardiovascular disease, including:

    1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the 3 months preceding screening), acute coronary syndrome within the 6 months preceding Screening, acute myocardial infarction within the 3 months preceding screening or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the 6 months preceding screening
    2. history of (within 3 months preceding Screening) or current unstable cardiac dysrhythmias
    3. uncontrolled hypertension (systolic blood pressure [BP] > 155 mmHg and/or diastolic BP > 95 mmHg)
    4. Stroke or transient ischemic attack within the 6 months preceding screening.
  10. Previous history of bladder disease and/or hematuria.
  11. Previous liver biopsy that demonstrated presence of cirrhosis or radiologic imaging consistent with cirrhosis or portal hypertension.
  12. Type 1 diabetes mellitus.
  13. Use of drugs that are known CYP2C8 inhibitors/substrate.
  14. Use of drugs associated with a clinical or histological picture consistent with fatty liver disease or NASH for more than 12 consecutive weeks in the 1 year prior to start of the study; (these include amiodarone, tamoxifen, methotrexate, glucocorticoids, anabolic steroids, tetracyclines, estrogens, valproate/valproic acid, chloroquine, anti-HIV drugs).
  15. History of thyroid disease (hypothyroid patients who are euthyroid on thyroid hormone replacement can be included).
  16. History of, or current, cardiac dysrhythmias.
  17. History of bariatric surgery, or undergoing evaluation for bariatric surgery.
  18. Patients with a >10% weight loss in the 3 months prior to screening.
  19. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the Investigator, unsuitable for the study (such as poorly controlled psychiatric disease, coronary artery disease, HIV or active gastrointestinal conditions that might interfere with drug absorption).
  20. Patients on any treatment with other drugs used for treatment of NASH [pentoxyphyllin, ursodeoxycholic acid, antioxidants such as vitamin E (>800 IU/day), glutathione, orlistat, betaine, incretin mimetics or non-prescribed complementary alternative medications (including dietary supplements, megadose vitamins, herbal preparations and special teas)] or any medicine in clinical trials for NASH. (However, patients who are taking stable dose of vitamin E for at least 3 months prior to screening will be enrolled in the study).
  21. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, hepatitis B virus (HBV) and hepatitis C virus (HCV), Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03863574


Contacts
Layout table for location contacts
Contact: Deven V Parmar, MD,FACP,FCP +971 43998280 deven.parmar@zydusdiscovery.ae
Contact: Richa P Vellanki Richa.Vellanki@zyduscadila.com

Locations
Layout table for location information
United States, Mississippi
Southern Therapy and Advanced Research (STAR) LLC Not yet recruiting
Jackson, Mississippi, United States, 39216
United States, Tennessee
Gastro One Not yet recruiting
Germantown, Tennessee, United States, 38138
Digestive Health Research Not yet recruiting
Hermitage, Tennessee, United States, 37076
United States, Texas
American Research Corporation Not yet recruiting
San Antonio, Texas, United States, 78215
Clinical Trials of Texas, Inc. Not yet recruiting
San Antonio, Texas, United States, 78229
United States, Virginia
Virginia Commonwealth University Not yet recruiting
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Zydus Discovery DMCC
Investigators
Layout table for investigator information
Study Director: Deven V Parmar, MD,FACP,FCP Zydus Discovery DMCC

Layout table for additonal information
Responsible Party: Zydus Discovery DMCC
ClinicalTrials.gov Identifier: NCT03863574     History of Changes
Other Study ID Numbers: SARO.17.004.02
First Posted: March 5, 2019    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Zydus Discovery DMCC:
NASH

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases